What is Entrada Therapeutics Earnings Power Value (EPV)?
As of Mar24, Entrada Therapeutics's earnings power value is $7.50. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Entrada Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Entrada Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics Earnings Power Value (EPV) Chart
|
Entrada Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
- |
|
Entrada Therapeutics Quarterly Data
|
|
Dec19 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Entrada Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Entrada Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Earnings Power Value (EPV) falls into.
Entrada Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Entrada Therapeutics (Entrada Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
6 Tide Street, Boston, MA, USA, 02210
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Executives
| Dipal Doshi |
director, officer: President and CEO |
C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
| Kory James Wentworth |
officer: Chief Financial Officer |
6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210 |
| Nathan J Dowden |
officer: Chief Operating Officer |
6 TIDE STREET, BOSTON MA 02210 |
| Nerissa Kreher |
officer: Chief Medical Officer |
C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139 |
| Gina Chapman |
director |
C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403 |
| Natarajan Sethuraman |
officer: Chief Scientific Officer |
6 TIDE STREET, BOSTON MA 02210 |
| Bernhardt G Zeiher |
director |
ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210 |
| Baker Bros. Advisors Lp |
10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Todd Foley |
director, 10 percent owner |
THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
| Felix Baker |
10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Julian Baker |
10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Baker Bros. Advisors (gp) Llc |
10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| John F Crowley |
director |
C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
| Redmile Group, Llc |
10 percent owner |
ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
| Mpm Bioventures 2018, L.p. |
10 percent owner |
450 KENDALL STREET, CAMBRIDGE MA 02142 |
Entrada Therapeutics (Entrada Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRDA has been successfully added to your